GVK Biosciences Joins ResearchPoint Global
Addition of India-based CRO expands reach of worldwide clinical organization
As the growth of India’s participation in global clinical programs continues to increase at a rapid pace, RPG strategically sought to expand its reach to this region. According to The Goldman Sachs Group, Inc., “India presents an attractive region for clinical trials given a population of over one billion, a large number of English-speaking patients, and a well developed information technology industry.” 1
RPG’s expansion into India offers numerous advantages for running clinical trials: a large population, qualified medical personnel, and well-established regulations. GVK BIO complements RPG’s current presence in the Americas, Europe (Western, Central, and Eastern) and Africa.
“RPG is strategically expanding our global footprint with qualified, like-minded CROs who have extensive drug development experience across a broad range of therapeutic areas,” said Matt Walker, Executive Vice President of Marketing and Business Development with ResearchPoint, a member of RPG. “GVK Biosciences has built an exceptional reputation as a full-service clinical service provider in India and we look forward to leveraging their deep local knowledge for the benefit of our clients.”
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.